SEI Investments
RLMD icon

SEI Investments’s Relmada Therapeutics RLMD Stock Holding History

SEI Investments’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$480K Sell
69,375
-97,239
-58% -$679K ﹤0.01% 2657
2026
Q1 		$1.16M Buy
166,614
+67,649
+68% +$320K ﹤0.01% 2287
2025
Q4 		$478K Buy
+98,965
New +$332K ﹤0.01% 2522
2025
Q2 		– Sell
-36,230
Closed -$9.78K – 2896
2025
Q1 		$9.78K Hold
36,230
– – ﹤0.01% 2750
2024
Q4 		$18.8K Sell
36,230
-90
-0.2% -$220 ﹤0.01% 2714
2024
Q3 		$118K Hold
36,320
– – ﹤0.01% 2540
2024
Q2 		$109K Hold
36,320
– – ﹤0.01% 2521
2024
Q1 		$169K Hold
36,320
– – ﹤0.01% 2452
2023
Q4 		$150K Buy
36,320
+90
+0.2% +$266 ﹤0.01% 2477
2023
Q3 		$109K Hold
36,230
– – ﹤0.01% 2506
2023
Q2 		$89.1K Sell
36,230
-739
-2% -$2.04K ﹤0.01% 2582
2023
Q1 		$83.5K Sell
36,969
-64,376
-64% -$222K ﹤0.01% 2595
2022
Q4 		$354K Buy
+101,345
New +$890K ﹤0.01% 2145

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SEI Investments's RLMD Position: Q2 2026 in Review

SEI Investments reduced its Relmada Therapeutics (RLMD) stake by 58% in Q2 2026, selling an estimated $679K and leaving 69,375 shares worth $480K. The position accounts for ﹤0.01% of the portfolio, ranked #2657.

SEI Investments first reported a position in RLMD in Q4 2022 and has held it in 13 quarters since. The position peaked at $1.16M in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • SEI Investments held 69,375 shares of Relmada Therapeutics worth $480K as of Q2 2026.
  • SEI Investments sold 97,239 Relmada Therapeutics shares in Q2 2026, an estimated $679K.
  • Relmada Therapeutics made up ﹤0.01% of SEI Investments's portfolio in Q2 2026, its #2657 holding.
  • SEI Investments first reported a position in Relmada Therapeutics in Q4 2022 and has held it in 13 quarters since.
  • SEI Investments's Relmada Therapeutics position peaked at $1.16M in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on SEI Investments's 13F filing for Q2 2026, filed 14 Aug 2026.